Trial reportScientific reports2026
Impact of FloTrac/EV1000-guided intraoperative hemodynamic optimization on postoperative outcomes in cardiac valve surgery: a randomized controlled trial.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04292951 (Early Goal Directed Therapy vs Standard Protocol for Hemodynamic Management in Patients Undergoing Cardiac Surgery), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Early Goal Directed Therapy vs Standard Protocol for Hemodynamic Management in Patients Undergoing Cardiac Surgery: A Randomized Controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac valve surgery is associated with significant postoperative morbidity and mortality. This study evaluated the impact of intraoperative hemodynamic optimization using FloTrac/EV1000 on postoperative outcomes in patients undergoing cardiac valve surgery. In this single-center, prospective, randomized controlled trial, 82 patients undergoing elective cardiac valve surgery were randomly allocated to either FloTrac/EV1000 management (EV1000 group, n = 42) or conventional management (Control group, n = 40). The primary outcome was ICU length of stay. Secondary outcomes included mechanical ventilation duration, hospital length of stay, vasoactive drug requirements, fluid balance, and postoperative complications. The EV1000 group had significantly shorter ICU (30.2%) and hospital (13.6%) stay (p = 0.007 and 0.047, respectively) compared to the Control group. The EV1000 group required more vasoactive drugs during pre-bypass (p = 0.018) but fewer before ICU transfer (p = 0.003) and during their ICU stay (p < 0.05). The incidence of postoperative ventricular fibrillation (0 vs. 15.0%, p = 0.011), bradycardia (11.9 vs. 35.0%, p = 0.016), atrial fibrillation with rapid ventricular response (14.3 vs. 25.0%, p = 0.032), acute respiratory distress syndrome (0 vs. 5.0%, p = 0.045), and acute kidney injury (0 vs. 5.0%, p = 0.045) was lower in the EV1000 group. Goal-directed hemodynamic management using FloTrac/EV1000 monitoring in cardiac valve surgery was associated with shorter ICU and hospital length of stay, reduced postoperative vasoactive drug requirements, and fewer postoperative complications compared with conventional management. Whether this benefit derives from the monitoring technology, the structured hemodynamic algorithm, or their combination warrants confirmation in future multicenter trials.Trial registration: NCT04292951 (The full date of first registration on https://ClinicalTrials.gov : March 1, 2020).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.